Extended Data Fig. 5: Forest plot of overall survival in prespecified subgroups with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥ 5.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
aNot reported, n = 28; bUnknown, n = 1; cInvalid/not reported, n = 74. Data are presented as unstratified hazard ratios and 95% CI. CapeOX, capecitabine plus oxaliplatin; chemo, chemotherapy; CI, confidence interval; CNS, central nervous system; CPS, combined positive score; EAC, oesophageal adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, 5-fluorouracil plus leucovorin plus oxaliplatin; GC, gastric cancer; GEJC, gastro-oesophageal junction cancer; HR, hazard ratio; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NIVO, nivolumab; OS, overall survival; PD-L1, programmed death ligand 1.
